Kudos for Kanabo as the LSE’s first listed cannabis-tech company
“…We’re talking about an addressable market for Kanabo of over 500 million euros in the next four years…”
‘Nature made precise’ is the catch phrase of Kanabo. But it’s more than a tag line; it’s at the heart of what the group does which is creating a new standard in the medical cannabis industry.
The Israeli-headquartered company has developed high-quality cannabis extract formulas administered by its medical-grade VapePod® vaporizer which have the trust of the physicians who will prescribe these dosable consumption and critically non-smoking solutions.
Patient access to products swiftly follows in the first half of this year and those interested in Kanabo’s wellness range without the psychoactive ingredient will soon be able to buy on the high street.
Chief executive and founder Avihu Tamir admits the greatest disappointment is not being at the London Stock Exchange in person on listing day. Like most Israel residents, he’s had his two vaccinations and can travel to the UK without quarantine, but was told he’d be the only person in the exchange to welcome the company to the UK investment fraternity.
Perhaps a portent of things to come however is that Kanabo is listing in the same month that UK-founded and former AIM-listed, cannabinoid focused GW pharmaceuticals was bought by Jazz Pharmaceuticals for approximately $7 billion.
There are similarities between Kanabo and GW. Both are science and patient driven with a desire to expand globally based on the belief there’s a bright future for cannabinoid solutions.
Here @AvihuTamir tells Sarah Lowther why the company is listing on the main board of the LSE, why he is confident that Kanabo (#KNB) can maintain its first mover advantage and how delighted he was with the pre-IPO book build.
The author was remunerated but does not hold shares in the company